Company / Interest Expense
Verrica Pharmaceuticals Inc. Interest Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.2M
FY2023
5-year range
$2.2M / $4.3M
FY2021-FY2023
Trend
-49.4%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2023.
Improved from $3M to $2M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, interest expense decreased 49.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.2M | -49.4% |
| FY2022 | $4.3M | +41.6% |
| FY2021 | $3.0M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026